Orion enters partnership with MSD, upgrades guidance

The US-based and Finnish firms will co-commercialize prostate cancer candidate ODM-208, and the deal has led Orion to raise its financial expectations.

Photo: MSD / PR

Pharmaceutical firm Orion has inked a deal with US-based MSD to co-develop and co-commercialize Orion’s prostrate cancer treatment candidate, ODM-208, the Finnish firm has announced in a press release.

Under the agreement, MSD will make an upfront USD 290m payment to Orion, of which around USD 60m will be spent on covering the Finnish firm’s ongoing development of the drug specifically designed to treat metastatic castration-resistant prostate cancer (mCRPC).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs